Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05594901
Active, not recruiting Observational

Impact of a Risk Stratification Tool on the Outcome of Liver Transplant Recipients Colonized With Carbapenem Resistant Enterobacteriaceae: an Observational Study

NCT05594901 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Bologna
Phase
Observational
Started
2022-11-01
Last updated
2025-03-25

Condition(s) studied

Liver TransplantationCarbapenem-Resistant Enterobacteriaceae Colonization

Investigational drug(s) / intervention(s)

Application of a prognostic score

Application of a prognostic score: The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.

Study summary

Although CRE infection after OLT have a dramatic impact on patient survival and several implementations have been proposed (i.e. preventive strategies or targeted surgical prophylaxis), a standardized approach in colonized patients is still missing. The investigators recently developed and internally validated a bed-side score to stratify the risk of CRE infection in OLT recipients colonized by CRE. The goal of this pre/post observational study is to investigate the impact on all-cause 90-day mortality in OLT recipients colonized with CRE using such score (CRECOOLT score) for the systematic evaluation of CRE infection risk.

The secondary objectives are:

* To analyse days of therapy with anti-CRE antibiotic regimens in patients with and without systematic evaluation of CRE infection risk, according to clinical practices.
* To evaluate rates of documented CRE infections and their relapses with selection of further resistance in patients with and without systematic evaluation of CRE infection risk.
* To evaluate the length of hospital, ICU stay and rates of hospital readmission in patients with and without systematic evaluation of CRE infection risk.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Signature of the informed consent * Age ≥ 18 years * CRE colonization within 60 days prior to or after transplantation Exclusion Criteria: * Patients receiving targeted antibiotic prophylaxis (against CRE) for a period longer than 48 hours * Patients receiving graft from a donor with cultures yielding a carbapenem-resistant Gram negative bacteria

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil
Università degli Studi di Padova - Unit Multivisceral Transplant Unit Padova Italy
Irccs Ismett Palermo Italy
ASST-Sette Laghi Università degli Studi dell'Insubria Varese Italy
Università degli Studi di Verona - Gastroenterologia Verona Italy
Hospital General Universitario Gregorio Maranon Madrid Spain

More University of Bologna trials in Italy

Study in Patients With Onychomycosis Treated With Mycoclear® and Ciclopirox Starting soon
Robotic vs Open Nephrectomy for ADPKD Active, not recruiting
The International Survey of Acute Coronary Syndromes-ARCHIVES Enrolling by invitation
Success and Survival Rate of Tranmucosal Versus Bone Level Implants: Randomized Clinical Trial Active, not recruiting
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy Active, not recruiting

Other trials for the same condition

Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients Starting soon
Electronic Archive of Internal Medicine for the Treatment of Severe Organ Failure and Liver Transplantation-MITIGO Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe Recruiting
HOPE Against Cancer Recurrence in HCC Recruiting
Intraoperatory Hemodynamic Monitoring in OLT Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05594901 on ClinicalTrials.gov ↗ ← All trials in Italy